{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Canakinumab+Injection", "query": { "intervention": "Canakinumab Injection" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 33, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Canakinumab+Injection&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T12:04:47.287Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00605475", "title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Canakinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 231, "start_date": "2007-12", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2012-02-13", "last_synced_at": "2026-09-03T12:04:47.287Z", "location_count": 6, "location_summary": "Little Rock, Arkansas • Miami, Florida • MD, Maryland + 2 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "MD", "state": "Maryland" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00605475" }, { "nct_id": "NCT01160822", "title": "To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Osteoarthritis" ], "interventions": [ { "name": "Canakinumab", "type": "BIOLOGICAL" }, { "name": "Placebo to canakinumab", "type": "DRUG" }, { "name": "Naproxen", "type": "DRUG" }, { "name": "Placebo to Naproxen", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 169, "start_date": "2010-04", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2012-10-30", "last_synced_at": "2026-09-03T12:04:47.287Z", "location_count": 8, "location_summary": "Anniston, Alabama • Mesa, Arizona • San Diego, California + 5 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Westlake Village", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01160822" }, { "nct_id": "NCT02272946", "title": "Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV", "Cardiovascular Disease" ], "interventions": [ { "name": "Canakinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Priscilla Hsue, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "59 Years", "sex": "ALL", "summary": "40 Years to 59 Years" }, "enrollment_count": 43, "start_date": "2015-09", "completion_date": "2021-12", "has_results": true, "last_update_posted_date": "2023-04-20", "last_synced_at": "2026-09-03T12:04:47.287Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02272946" }, { "nct_id": "NCT05984602", "title": "A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Canakinumab", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 9, "start_date": "2023-07-14", "completion_date": "2026-07-01", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-09-03T12:04:47.287Z", "location_count": 3, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05984602" }, { "nct_id": "NCT00886769", "title": "Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Juvenile Idiopathic Arthritis" ], "interventions": [ { "name": "Canakinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "19 Years", "sex": "ALL", "summary": "2 Years to 19 Years" }, "enrollment_count": 84, "start_date": "2009-07", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2017-03-29", "last_synced_at": "2026-09-03T12:04:47.287Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00886769" }, { "nct_id": "NCT00685373", "title": "Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cryopyrin-Associated Periodic Syndromes", "Familial Cold Autoinflammatory Syndrome", "Muckle Wells Syndrome", "Neonatal Onset Multisystem Inflammatory Disease" ], "interventions": [ { "name": "Canakinumab (ACZ885)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 166, "start_date": "2008-05", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2016-11-04", "last_synced_at": "2026-09-03T12:04:47.287Z", "location_count": 6, "location_summary": "Little Rock, Arkansas • San Francisco, California • Columbus, Georgia + 3 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00685373" }, { "nct_id": "NCT02900664", "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma" ], "interventions": [ { "name": "PDR001", "type": "BIOLOGICAL" }, { "name": "ACZ885", "type": "BIOLOGICAL" }, { "name": "CJM112", "type": "BIOLOGICAL" }, { "name": "TMT212", "type": "DRUG" }, { "name": "EGF816", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 283, "start_date": "2016-08-23", "completion_date": "2021-03-17", "has_results": false, "last_update_posted_date": "2022-03-29", "last_synced_at": "2026-09-03T12:04:47.287Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Nashville, Tennessee + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02900664" }, { "nct_id": "NCT00889863", "title": "Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Juvenile Idiopathic Arthritis With Active Flare" ], "interventions": [ { "name": "canakinumab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "19 Years", "sex": "ALL", "summary": "2 Years to 19 Years" }, "enrollment_count": 177, "start_date": "2009-07", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2012-10-16", "last_synced_at": "2026-09-03T12:04:47.287Z", "location_count": 12, "location_summary": "Little Rock, Arkansas • Washington D.C., District of Columbia • Chicago, Illinois + 6 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00889863" }, { "nct_id": "NCT05467800", "title": "Study of Canakinumab in Patients With Myelofibrosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Myelofibrosis", "Post-essential Thrombocythemia Myelofibrosis", "ET-MF", "Post-polycythemia Vera Related Myelofibrosis", "PV-MF" ], "interventions": [ { "name": "Canakinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John Mascarenhas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2022-08-02", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-09-03T12:04:47.287Z", "location_count": 7, "location_summary": "Los Angeles, California • Tampa, Florida • Westwood, Kansas + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Westwood", "state": "Kansas" }, { "city": "New York", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05467800" }, { "nct_id": "NCT05080218", "title": "COVID-19 VaccinE Response in Rheumatology Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis", "Psoriatic Arthritis", "Spondylarthritis" ], "interventions": [ { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Abatacept", "type": "DRUG" }, { "name": "Secukinumab", "type": "DRUG" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "TNF Inhibitor", "type": "DRUG" }, { "name": "Canakinumab Injection", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "Ixekizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jeffrey Curtis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 841, "start_date": "2021-11-15", "completion_date": "2024-05-28", "has_results": false, "last_update_posted_date": "2025-05-02", "last_synced_at": "2026-09-03T12:04:47.287Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hoover", "state": "Alabama" }, { "city": "Hoover", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05080218" } ] }